Glenmark Pharmaceuticals has unveiled the launch of Empagliflozin and its fixed-combination drugs in India, named Glempa, Glempa-L, and Glempa-M.
The stocks of Glenmark Pharmaceuticals Limited were trading at ₹1,390.85, showing an increase of ₹9.35 or 0.67 per cent on the NSE at 12:37 pm today.
Empagliflozin and its combinations, as SGLT2 inhibitors, aim to enhance glycemic control in adults with type 2 diabetes mellitus (T2DM) while lowering cardiovascular risks. Clinical trials have demonstrated a 14 per cent reduction in major cardiovascular events in T2DM patients with high CV risks using Empagliflozin.
Alok Malik, President and Head of India Formulations Business, stated, “Glenmark has a strong history of introducing innovative and accessible treatments for Cardiometabolic care in India. The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution.”
The Glempa product line consists of three options: Glempa (Empagliflozin 10mg/25mg) for standalone treatment, Glempa-L (Empagliflozin with Linagliptin) for dual-action therapy, and Glempa-M (Empagliflozin with Metformin) for enhanced glycemic control.
According to IQVIA data, the market for Empagliflozin and combinations in India was valued at 642 crore for the 12-month period ending January 2025.
This launch follows Glenmark’s introduction of Lirafit in 2024, a biosimilar for Liraglutide, marking their entry into the injectable anti-diabetic market as part of their expanding cardiometabolic portfolio.
Published on March 12, 2025.
